Revvity, Inc. (NYSE:RVTY) Shares Sold by First National Bank of Omaha

First National Bank of Omaha decreased its holdings in Revvity, Inc. (NYSE:RVTY) by 10.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 89,692 shares of the company’s stock after selling 10,664 shares during the quarter. First National Bank of Omaha’s holdings in Revvity were worth $11,458,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. CWM LLC increased its stake in shares of Revvity by 13.4% during the second quarter. CWM LLC now owns 2,697 shares of the company’s stock valued at $283,000 after acquiring an additional 319 shares during the period. SG Americas Securities LLC raised its stake in shares of Revvity by 15.4% in the 2nd quarter. SG Americas Securities LLC now owns 20,144 shares of the company’s stock worth $2,112,000 after buying an additional 2,693 shares in the last quarter. Czech National Bank lifted its holdings in shares of Revvity by 8.3% in the second quarter. Czech National Bank now owns 23,513 shares of the company’s stock valued at $2,466,000 after buying an additional 1,800 shares during the period. Artemis Investment Management LLP grew its holdings in Revvity by 21.3% during the second quarter. Artemis Investment Management LLP now owns 107,634 shares of the company’s stock worth $11,287,000 after acquiring an additional 18,916 shares during the period. Finally, Sequoia Financial Advisors LLC raised its position in Revvity by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 23,374 shares of the company’s stock worth $2,451,000 after acquiring an additional 525 shares in the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Stock Performance

RVTY opened at $116.46 on Friday. The stock has a 50-day moving average of $118.87 and a 200-day moving average of $116.23. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.97 and a current ratio of 3.56. Revvity, Inc. has a 52-week low of $88.90 and a 52-week high of $129.50. The company has a market cap of $14.17 billion, a PE ratio of 56.26, a price-to-earnings-growth ratio of 3.57 and a beta of 1.03.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Monday, November 4th. The company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.15. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The company had revenue of $684.10 million for the quarter, compared to analyst estimates of $679.66 million. During the same quarter last year, the firm posted $1.18 earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts forecast that Revvity, Inc. will post 4.85 earnings per share for the current fiscal year.

Revvity announced that its Board of Directors has approved a stock repurchase plan on Monday, November 4th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to reacquire up to 6.5% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. Revvity’s dividend payout ratio (DPR) is presently 13.53%.

Insider Buying and Selling at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 2,154 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the sale, the insider now directly owns 19,652 shares of the company’s stock, valued at approximately $2,392,237.96. This represents a 9.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

RVTY has been the subject of several research reports. Raymond James raised their price objective on shares of Revvity from $144.00 to $146.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Leerink Partners raised their target price on shares of Revvity from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Barclays dropped their price target on Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a report on Monday, November 25th. Wells Fargo & Company began coverage on Revvity in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $130.00 price objective for the company. Finally, Sanford C. Bernstein cut their target price on Revvity from $150.00 to $145.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Revvity currently has an average rating of “Moderate Buy” and a consensus price target of $131.73.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.